The FDA approved Boehringer's nerandomilast, now Jascayd, as the first new U.S. treatment for idiopathic pulmonary fibrosis ...

Nerandomilast appears to reduce the risk of death in people with IPF and PPF, according to analyses of clinical trial data.

Columnist Sam Kirton's diagnostic journey was relatively short compared with that of other idiopathic pulmonary fibrosis (IPF) patients.

In just over a month, one of the largest gatherings of pulmonary fibrosis (PF) patients, caregivers, and health professionals will take place in Chicago, at the Pulmonary Fibrosis Foundation (PFF) ...

The National Institutes of Health has awarded $219,000 to fund a project at the University of Texas at Tyler aimed at developing a treatment for radiation-induced pulmonary fibrosis (PF) which can ...

BMS-986020 is an anti-fibrotic drug being developed by Bristol-Myers Squibb, and is chemically a lysophosphatidic acid (LPA) receptor antagonist. The drug, an oral formulation, is in clinical trials ...

Researchers have developed an inhalable prototype medicine that may be able to repair lung scarring caused by idiopathic pulmonary fibrosis (IPF) by stimulating the growth of stem cells directly in ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).